SLC7A11/xCT在肝脏疾病中的研究进展

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF (2195 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肝脏作为人体内最大的消化器官，参与物质代谢、蛋白合成、解毒、凝血和免疫等各种与生命活动密切相关的生物学功能。溶质载体家族7成员11(solute carrier family 7 member 11，SLC7A11/xCT)是一种介导氨基酸转运的跨膜蛋白。随着相关研究的逐步深入，越来越多的证据表明SLC7A11参与多种肝脏疾病的病理生理过程。SLC7A11可以调节氨基酸代谢、氧化还原稳态及铁死亡等病理过程，同时近期研究发现其在一种全新的细胞死亡类型——双硫死亡(disulfidptosis)中发挥重要的作用。本文针对近年来SLC7A11的相关研究进行综述，阐述SLC7A11在肝脏疾病中的作用及调节机制，为以SLC7A11为靶点的肝脏疾病的治疗策略提供新的参考和依据。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	兰玥1
	严文静1
	2
	王雯1
	2

关键词 ：溶质载体家族7成员11(SLC7A11), xCT, 双硫死亡, 铁死亡, 肝脏疾病, 急性肝损伤, 表观遗传

收稿日期: 2023-03-14

基金资助:国家自然科学基金资助项目(32071134)

通讯作者: 王雯(通讯作者)，教授，博士生导师，E-mail：wangwen@ccmu.edu.cn

作者简介: 兰玥(2000—)，女，2018级基础医学专业本科生；

引用本文:

兰玥1，严文静1,2，王雯1,2. SLC7A11/xCT在肝脏疾病中的研究进展[J]. 江苏大学学报:医学版, 2023, 33(05): 404-411.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2023/V33/I05/404

［1］Kandasamy P, Gyimesi G, Kanai Y, et al. Amino acid transporters revisited: New views in health and disease\[J\]. Trends Biochem Sci, 2018, 43(10): 752-789.
［2］Lu SC. Glutathione synthesis\[J\]. Biochim Biophys Acta, 2013, 1830(5): 3143-3153.
［3］Robert SM, Buckingham SC, Campbell SL, et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma\[J\]. Sci Transl Med, 2015, 7(289): 289ra86.
［4］Shin CS, Mishra P, Watrous JD, et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility\[J\]. Nat Commun, 2017, 8: 15074.
［5］Liu X, Nie L, Zhang Y, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis\[J\]. Nat Cell Biol, 2023, 25(3): 404-414.
［6］Samra YA, Hamed MF, ElSheakh AR. Hepatoprotective effect of allicin against acetaminopheninduced liver injury: Role of inflammasome pathway, apoptosis, and liver regeneration\[J\]. J Biochem Mol Toxicol, 2020, 34(5): e22470.
［7］Du K, Oh SH, Dutta RK, et al. Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells but exacerbates chronic liver injury\[J\]. Liver Int, 2021, 41(9): 2214-2227.
［8］Liu CY, Wang M, Yu HM, et al. Ferroptosis is involved in alcoholinduced cell death in vivo and in vitro\[J\]. Biosci Biotechnol Biochem, 2022, 84(8): 1621-1628.
［9］Friedman SL, NeuschwanderTetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies\[J\]. Nat Med, 2018, 24(7): 908-922.
［10］Wada F, Koga H, Akiba J, et al. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine\[J\]. Cancer Sci, 2018, 109(9): 2801-2810.
［11］Tang X, Chen W, Liu H, et al. Research progress on SLC7A11 in the regulation of cystine/cysteine metabolism in tumors\[J\]. Oncol Lett, 2022, 23(2): 47.
［12］Fotiadis D, Kanai Y, Palacín M. The SLC3 and SLC7 families of amino acid transporters\[J\]. Mol Aspects Med, 2013, 34(2/3): 139-158.
［13］Kinoshita H, Okabe H, Beppu T, et al. Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma\[J\]. Oncol Rep, 2013, 29(2): 685-689.
［14］Bianco A, Perrotta F, Barra G, et al. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer\[J\]. Int J Mol Sci, 2019, 20(19): 4931.
［15］Ma MZ, Chen G, Wang P, et al. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSHdependent mechanism\[J\]. Cancer Lett, 2015, 368(1): 88-96.
［16］Kandasamy P, Gyimesi G, Kanai Y, et al. Amino acid transporters revisited: New views in health and disease\[J\]. Trends Biochemical Sci, 2018, 43(10): 752-789.
［17］Combs JA, DeNicola GM. The nonessential amino acid cysteine becomes essential for tumor proliferation and survival\[J\]. Cancers (Basel)， 2019, 11(5): 678.
［18］芦为康, 杭黎华, 李帅, 等. 铁死亡机制及其在胃肠道疾病中的研究进展\[J\]. 江苏大学学报(医学版), 2023, 33(1): 23-28, 36.
［19］Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy\[J\]. Protein Cell, 2021, 12(8): 599-620.
［20］Qiao HX, Hao CJ, Li Y, et al. JNK activation mediates the apoptosis of xCTdeficient cells\[J\]. Biochem Biophys Res Commun, 2008, 370(4): 584-588.
［21］Yoshikawa M, Tsuchihashi K, Ishimoto T, et al. xCT inhibition depletes CD44vexpressing tumor cells that are resistant to EGFRtargeted therapy in head and neck squamous cell carcinoma\[J\]. Cancer Res, 2013, 73(6): 1855-1866.
［22］Dai L, Cao Y, Chen Y, et al. Targeting xCT, a cystineglutamate transporter induces apoptosis and tumor regression for KSHV/HIVassociated lymphoma\[J\]. J Hematol Oncol, 2014, 7: 30.
［23］Hu K, Li K, Lv J, et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRASmutant lung adenocarcinoma\[J\]. J Clin Invest, 2020, 130(4): 1752-1766.
［24］Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: An irondependent form of nonapoptotic cell death\[J\]. Cell, 2012, 149(5): 1060-1072.
［25］Liu X, Olszewski K, Zhang Y, et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer\[J\]. Nat Cell Biol, 2020, 22(4): 476-486.
［26］Koppula P, Zhang Y, Shi J, et al. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate\[J\]. J Biol Chem, 2017, 292(34): 14240-14249.
［27］PakosZebrucka K, Koryga I, Mnich K, et al. The integrated stress response\[J\]. EMBO Rep, 2016, 17(10): 1374-1395.
［28］Kilberg MS, Shan J, Su N. ATF4dependent transcription mediates signaling of amino acid limitation\[J\]. Trends Endocrinol Metab, 2009, 20(9): 436-443.
［29］Ye P, Mimura J, Okada T, et al. Nrf2 and ATF4dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition\[J\]. Mol Cell Biol, 2014, 34(18): 3421-3434.
［30］Jiang L, Kon N, Li T, et al. Ferroptosis as a p53mediated activity during tumour suppression\[J\]. Nature, 2015, 520(7545): 57-62.
［31］Clemons NJ, Liu DS, Duong CP, et al. Inhibiting system xC- and glutathione biosynthesisa potential Achilles′ heel in mutantp53 cancers\[J\]. Mol Cell Oncol, 2017, 4(5): e1344757.
［32］Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals\[J\]. Nat Genet, 2003, 33(1): S245-S254.
［33］Zhang Y, Shi J, Liu X, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression\[J\]. Nat Cell Biol, 2018, 20(10): 1181-1192.
［34］Sui S, Zhang J, Xu S, et al. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)JQ1 in cancer cells\[J\]. Cell Death Dis, 2019, 10(5): 331.
［35］Ogiwara H, Takahashi K, Sasaki M, et al. Targeting the vulnerability of glutathione metabolism in ARID1A defificient cancers\[J\]. Cancer Cell, 2019, 35(5): 177-190.
［36］Liu T, Jiang L, Tavana O, et al. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11\[J\]. Cancer Res, 2019, 79(8): 1913-1924.
［37］Zhao X, Zhou M, Yang Y, et al. The ubiquitin hydrolase OTUB1 promotes glioma cell stemness via suppressing ferroptosis through stabilizing SLC7A11 protein\[J\]. Bioengineered, 2021, 12(2): 12636-12645.
［38］Yamaguchi I, Yoshimura SH, Katoh H. High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11)\[J\]. J Biol Chem, 2020, 295(20): 6936-6945.
［39］Gu Y, Albuquerque CP, Braas D, et al. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystineglutamate antiporter xCT\[J\]. Mol Cell, 2017, 67(1): 128-138.
［40］Kim J, Guan KL. mTOR as a central hub of nutrient signalling and cell growth\[J\]. Nat Cell Biol, 2019, 21(1): 63-71.
［41］Tsuchihashi K, Okazaki S, Ohmura M, et al. The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-)\[J\]. Cancer Res, 2016, 76(10): 2954-2963.
［42］Stravitz RT, Lee WM. Acute liver failure\[J\]. Lancet, 2019, 394(9736): 190-201.
［43］Crismale JF, Friedman SL. Acute liver injury and decompensated cirrhosis\[J\]. Med Clin North Am, 2020, 104(4): 647-662.
［44］Weigand K, Brost S, Steinebrunner N, et al. Ischemia/reperfusion injury in liver surgery and transplantation: pathophysiology\[J\]. HPB Surg, 2012, 2012(1): 176723.
［45］Qi D, Chen P, Bao H, et al. Dimethyl fumarate protects against hepatic ischemiareperfusion injury by alleviating ferroptosis via the NRF2/SLC7A11/HO1 axis\[J\]. Cell Cycle, 2023, 22(7): 818-828.
［46］Du WJ, Liu L, Sun C, et al. Prodromal fever indicates a high risk of liver failure in acute hepatitis B\[J\]. Int J Infect Dis, 2017, 57(1): 98-103.
［47］Liu GZ, Xu XW, Tao SH, et al. HBx facilitates ferroptosis in acute liver failure via EZH2 mediated SLC7A11 suppression\[J\]. J Biomed Sci, 2021, 28(1): 67.
［48］Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world\[J\]. J Hepatol, 2019, 70(1): 151-171.
［49］Campana L, Iredale JP. Regression of liver fibrosis\[J\]. Semin Liver Dis, 2017, 37(1): 1-10.
［50］Friedman SL, Rockey DC, McGuire RF, et al. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture\[J\]. Hepatology, 1992, 15(2): 234-243.
［51］Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis\[J\]. Apoptosis, 2005, 10(5): 927-939.
［52］Xie L, Tang H, Song J, et al. Chrysophanol: a review of its pharmacology, toxicity and pharmacokinetics\[J\]. J Pharm Pharmacol, 2019, 71(10): 1475-1487.
［53］Kuo CY, Chiu V, Hsieh PC, et al. Chrysophanol attenuates hepatitis B virus X proteininduced hepatic stellate cell fibrosis by regulating endoplasmic reticulum stress and ferroptosis\[J\]. J Pharmacol Sci, 2020, 144(3): 172-182.
［54］Banik K, Khatoon E, Harsha C, et al. Wogonin and its analogs for the prevention and treatment of cancer: A systematic review\[J\]. Phytother Res, 2022, 36(5): 1854-1883.
［55］Liu G, Wei C, Yuan S, et al. Wogonoside attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis through SOCS1/P53/SLC7A11 pathway\[J\]. Phytother Res, 2022, 36(11): 4230-4243.
［56］Corpechot C, Barbu V, Wendum D, et al. Hypoxiainduced VEGF and collagen Ⅰ expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis\[J\]. Hepatology, 2002, 35(5): 1010-1021.
［57］Wang Y, Gao J, Zhang D, et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis\[J\]. J Hepatol, 2010, 53(1): 132-144.
［58］Yuan S, Wei C, Liu G, et al. Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF1α/SLC7A11 pathway\[J\]. Cell Prolif, 2022, 55(1): e13158.
［59］Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention\[J\]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20.
［60］Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensusdriven proposed nomenclature for metabolic associated fatty liver disease\[J\]. Gastroenterology, 2020, 158(7): 1999-2014.e1.
［61］Altomare AA, Aiello G, Garcia JL, et al. Protein profiling of a cellular model of NAFLD by advanced bioanalytical approaches\[J\]. Int J Mol Sci, 2022, 23(16): 9025.
［62］Tanase DM, Gosav EM, Costea CF, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)\[J\]. J Diabetes Res, 2020, 2020: 3920196.
［63］Li D, Jiang C, Mei G, et al. Quercetin alleviates ferroptosis of pancreatic β cells in type 2 diabetes\[J\]. Nutrients, 2020, 12(10): 2954.
［64］Manthey J, Shield KD, Rylett M, et al. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study\[J\]. Lancet, 2019, 393(10190): 2493-2502.
［65］Dodson M, CastroPortuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis\[J\]. Redox Biol, 2020, 23(1): 101107.
［66］Zhang Y, Zhao S, Fu Y, et al. Computational repositioning of dimethyl fumarate for treating alcoholic liver disease\[J\]. Cell Death Dis, 2020, 11(8): 641.
［67］Schlageter M, Terracciano LM, D′Angelo S, et al. Histopathology of hepatocellular carcinoma\[J\]. World J Gastroenterol, 2014, 20(43): 15955-15964.
［68］Liu L, Zhu XD, Wang WQ, et al. Activation of βcatenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis\[J\]. Clin Cancer Res, 2010, 16(10): 2740-2750.
［69］Kinoshita H, Okabe H, Beppu T, et al. Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma\[J\]. Oncol Rep, 2013, 29(2): 685-689.
［70］Kim DH, Kim WD, Kim SK, et al. TGFβ1mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells\[J\]. Cell Death Dis, 2020, 11(5): 406.
［71］Chen Q, Zheng W, Guan J, et al. SOCS2enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma\[J\]. Cell Death Differ, 2023, 30(1): 137-151.
［72］Oda K, Lee Y, Wiriyasermkul P, et al. Consensus mutagenesis approach improves the thermal stability of system xC- transporter, xCT, and enables cryoEM analyses\[J\]. Protein Sci, 2020, 29(12): 2398-2407.
［73］Yan R, Xie E, Li Y, et al. The structure of erastinbound xCT4F2hc complex reveals molecular mechanisms underlying erastininduced ferroptosis\[J\]. Cell Res, 2022, 32(7): 687-690.
［74］Ruiu R, Rolih V, Bolli E, et al. Fighting breast cancer stem cells through the immunetargeting of the xCT cystineglutamate antiporter\[J\]. Cancer Immunol Immunother, 2019, 68(1): 131-141.